Pfizer has sold its 49-percent state in a joint venture with Chinese firm Hisun Pharmaceuticals, Bloomberg reported Friday.
The $295-million partnership forged in 2011 aimed to develop, manufacture and commercialise pharmaceutical products in China and other regions.
Pfizer spokesperson Steve Danehy did not divulge how much Pfizer will receive from the transaction.
"We will continue to collaborate with the [Chinese] government and other stakeholders to increase access to affordable and high quality medicines," Danehy stated.
To read more NewsPoints articles, click here.
About FirstWord Pharma | Refer a Colleague | Upgrade Your FirstWord Pharma | Contact FirstWord Pharma | FirstWord Reports
Advertise with FirstWord Pharma | Industry Partner Showcase
All Contents Copyright © 2019 Doctor's Guide Publishing Limited. All Rights Reserved.
Terms of Use | Privacy Policy